Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

- Approximately 1,000 patients in the U.S. 12 years of age and older are now eligible for this one-time treatment -

...

Related Keywords

Australia ,London ,City Of ,United Kingdom ,United States ,Boston ,Massachusetts ,America ,Reshma Kewalramani ,Companies To Work ,Vertex Pharmaceuticals Incorporated Nasdaq ,Instagram ,Youtube ,Exchange Commission ,Linkedin ,Facebook ,Drug Administration ,Vertex Pharmaceuticals Incorporated ,Chief Executive Officer ,Transfusion Dependent Beta Thalassemia ,Vertex Connects ,Care Managers ,Prescribing Information ,Patient Information ,North America ,Latin America ,Top Employers ,Private Securities Litigation Reform Act ,Markets ,